Infusystem Hld Stock Price, News & Analysis

InfuSystem Holdings, Inc. (NYSE American: INFU) announced its third quarter 2022 financial results will be issued on November 8, 2022, before the market opens. A conference call will follow at 9:00 a.m. Eastern Time to discuss the financial outcomes. Interested parties can join by dialing (833) 366-1127 or via a live webcast on the company’s website. InfuSystem provides healthcare services focusing on outpatient care for durable medical equipment manufacturers, with operations across several U.S. states and Canada.

InfuSystem Holdings, Inc. (NYSE American: INFU) appointed R. Rimmy Malhotra as an independent director, effective September 20, 2022. Malhotra, who invested in the company in 2012, brings valuable insights on investments and capital allocation. His appointment is expected to enhance the company’s governance and strategic direction as it aims for long-term growth. Malhotra has extensive experience in investment and management, serving as Vice Chairman of HireQuest Inc. and on various other boards, complementing InfuSystem's focus on outpatient care for durable medical equipment.

InfuSystem Holdings, Inc. (NYSE American: INFU) announced participation in Lake Street Capital Markets' 6th Annual Best Ideas Growth (BIG6) Conference on September 14, 2022, in New York City. CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance will engage in one-on-one and group meetings with investors. The BIG6 Conference is an exclusive event that connects top public companies with institutional investors. InfuSystem specializes in outpatient care and durable medical equipment services, focusing on Integrated Therapy Services and Durable Medical Equipment Services.

InfuSystem Holdings reported Q2 2022 net revenues of $27 million, marking a 9% increase year-over-year. Integrated Therapy Services (ITS) revenues grew 6% to $17.2 million, while Durable Medical Equipment (DME) revenues surged 15% to $9.8 million. Despite revenue growth, gross profit fell 1% to $14.9 million with a gross margin decline to 55.1%. The company posted a net loss of $0.2 million or $(0.01) per diluted share. Adjusted EBITDA was $5.5 million, a 6% decrease. Full-year revenue guidance was revised to 10%-13% growth.

InfuSystem Holdings, Inc. (NYSE American: INFU) has announced the release of its second quarter 2022 financial results on August 4, 2022, before market opening. A subsequent conference call will be held at 9:00 a.m. Eastern Time on the same day to discuss these results. InfuSystem specializes in outpatient care services for durable medical equipment, operating two main platforms: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME). Services include oncology, pain management, and more.

InfuSystem Holdings, Inc. (NYSE American: INFU) has announced a national sales and marketing agreement with Ventis Pharma for its Endura-Kit™, a patented local anesthetic compound. This collaboration aims to enhance pain management solutions, focusing on opioid alternatives through multi-modal approaches. The Endura-Kit™ combines three non-opioid drugs, designed to improve post-operative and chronic pain management effectively. This partnership is expected to expand InfuSystem's revenue streams and enhance their service offerings.

InfuSystem Holdings, Inc. (NYSE American: INFU) announced that its CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance will participate in the Craig-Hallum's 19th Annual Institutional Investor Conference on June 1, 2022. This event will be held virtually, and management will conduct one-on-one meetings throughout the day. Interested investors can reach out to Craig-Hallum or contact Lytham Partners at 602-889-9700 or via email at infu@lythampartners.com. InfuSystem is a national healthcare service provider, specializing in outpatient care for durable medical equipment.

InfuSystem Holdings, Inc. (NYSE: INFU) announced a 9% revenue increase for Q1 2022, totaling $26.8 million. Growth was driven by a 5% rise in Integrated Therapy Services and an 18% rise in Durable Medical Equipment Services. Although gross profit rose to $15.4 million, the gross margin decreased to 57.4%. InfuSystem signed a three-year Master Service Agreement with a leading medical technology company, potentially generating $10-12 million in annual revenue. Operating cash flow surged 54% to $4.1 million, but a net loss of $0.4 million was reported. The company expects 15-20% revenue growth for the full year.

InfuSystem Holdings, Inc. (NYSE American: INFU) has secured a three-year master service agreement with a leading global healthcare technology company, effective April 25, 2022. This agreement involves providing maintenance and repair services for over 300,000 infusion pumps across more than 1,200 medical facilities in North America. The estimated annual revenue from this contract is between $10 million and $12 million. The CEO emphasizes this partnership as a foundation for growth in their Durable Medical Equipment (DME) services segment.